Literature DB >> 19210909

Lambert-eaton myasthenic syndrome.

Maria B Weimer1, Joaquin Wong.   

Abstract

Lambert Eaton myasthenic syndrome (LEMS) is a rare neuromuscular junction disease. Often, the signs and symptoms of LEMS are mistaken for myasthenia gravis and therefore the workup is misdirected. A physician must look for an occult malignancy when the diagnosis is made and then continue to search for a malignancy for at least 5 years after diagnosis. The diagnosis of LEMS can be confirmed with electrophysiologic studies or with serum calcium channel antibodies. In most patients with LEMS, 3,4-diaminopyridine will improve strength. In patients without malignancy, immunosuppressants do have a role in the treatment of LEMS. Patients and physicians must be aware that certain situations and drugs may exacerbate weakness.

Entities:  

Year:  2009        PMID: 19210909     DOI: 10.1007/s11940-009-0010-z

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  36 in total

Review 1.  Available treatment options for the management of Lambert-Eaton myasthenic syndrome.

Authors:  Jan J G M Verschuuren; Paul W Wirtz; Maarten J Titulaer; Luuk N A Willems; Joop van Gerven
Journal:  Expert Opin Pharmacother       Date:  2006-07       Impact factor: 3.889

2.  IgG from patients with Lambert-Eaton syndrome blocks voltage-dependent calcium channels.

Authors:  Y I Kim; E Neher
Journal:  Science       Date:  1988-01-22       Impact factor: 47.728

3.  Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome.

Authors:  J Newsom-Davis; N M Murray
Journal:  Neurology       Date:  1984-04       Impact factor: 9.910

Review 4.  Treatment for Lambert-Eaton myasthenic syndrome.

Authors:  P Maddison; J Newsom-Davis
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

5.  Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families.

Authors:  Paul W Wirtz; Jennifer Bradshaw; Axel R Wintzen; Jan J Verschuuren
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

6.  Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis.

Authors:  Rainer Linke; Mira Schroeder; Thomas Helmberger; Raymond Voltz
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

7.  Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine.

Authors:  H Lundh; O Nilsson; I Rosén
Journal:  Neurology       Date:  1984-10       Impact factor: 9.910

8.  The carcinomatous neuromyopathy of oat cell lung cancer.

Authors:  R J Hawley; M H Cohen; N Saini; V W Armbrustmacher
Journal:  Ann Neurol       Date:  1980-01       Impact factor: 10.422

9.  The Lambert-Eaton myasthenic syndrome. A review of 50 cases.

Authors:  J H O'Neill; N M Murray; J Newsom-Davis
Journal:  Brain       Date:  1988-06       Impact factor: 13.501

Review 10.  Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders.

Authors:  Z Argov; Y Shapira; L Averbuch-Heller; I Wirguin
Journal:  Muscle Nerve       Date:  1995-07       Impact factor: 3.217

View more
  3 in total

Review 1.  Voltage gated calcium channel antibody-related neurological diseases.

Authors:  Can Ebru Bekircan-Kurt; Eda Derle Çiftçi; Aslı Tuncer Kurne; Banu Anlar
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

2.  Lambert-Eaton myasthenic syndrome as a cause of persistent neuromuscular weakness after a mediastinoscopic biopsy -A case report-.

Authors:  Cheol Jin Lee; Se Hun Lim; Chee Mahn Shin; Young Jae Kim; Young Kyun Choe; Soon Ho Cheong; Kun Moo Lee; Jeong Han Lee; Young Hwan Kim; Kwang Rae Cho; Sang Eun Lee; Jong Suk Bae
Journal:  Korean J Anesthesiol       Date:  2010-07-21

3.  Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy.

Authors:  Nils Erik Gilhus
Journal:  Autoimmune Dis       Date:  2011-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.